Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vaxcyte (PCVX) Operating Expenses (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Operating Expenses data on record, last reported at $345.8 million in Q1 2026.

  • On a quarterly basis, Operating Expenses rose 91.3% to $345.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.1 billion, a 71.22% increase, with the full-year FY2025 number at $923.7 million, up 62.18% from a year prior.
  • Operating Expenses reached $345.8 million in Q1 2026 per PCVX's latest filing, up from $274.3 million in the prior quarter.
  • Over the last five years, Operating Expenses for PCVX hit a ceiling of $345.8 million in Q1 2026 and a floor of $39.2 million in Q1 2022.
  • A 5-year average of $149.4 million and a median of $139.9 million in 2024 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: soared 190.07% in 2022, then dropped 17.55% in 2024.
  • Tracing PCVX's Operating Expenses over 5 years: stood at $86.6 million in 2022, then skyrocketed by 127.18% to $196.7 million in 2023, then decreased by 17.55% to $162.2 million in 2024, then surged by 69.13% to $274.3 million in 2025, then rose by 26.09% to $345.8 million in 2026.
  • Business Quant data shows Operating Expenses for PCVX at $345.8 million in Q1 2026, $274.3 million in Q4 2025, and $242.4 million in Q3 2025.